2025-09-28 - Analysis Report
Okay, here's an analysis of TG Therapeutics (TGTX) based on the provided information.

## TGTX Stock Analysis

**Ticker:** TGTX (TG Therapeutics Inc)

**Company Overview:** TG Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 267.5%
*   **VOO Cumulative Return:** 66.4%
*   **Absolute Divergence:** 35.9
*   **Relative Divergence:** 37.4

**Analysis:** TGTX has significantly outperformed the S&P 500 (VOO) over the analyzed period. The relative divergence indicates that TGTX's current performance is in the lower end of its historical outperformance range compared to VOO.

**Alpha, Beta Analysis Table:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2015-2017  | 1.0%   | 73.9%  | -8.0%   | -0.0   | 1.3    |
| 2016-2018  | -18.0%  | 73.9%  | -16.0%  | -0.0   | 0.7    |
| 2017-2019  | 69.0%   | 74.2%  | 65.0%   | 0.0    | 1.8    |
| 2018-2020  | 351.0%  | 74.2%  | 325.0%  | 0.1    | 8.2    |
| 2019-2021  | 145.0%  | 74.2%  | 116.0%  | 0.3    | 3.0    |
| 2020-2022  | -68.0%  | 77.8%  | -83.0%  | 0.0    | 1.9    |
| 2021-2023  | -211.0% | 77.8%  | -229.0% | -0.4   | 2.7    |
| 2022-2024  | 201.0%  | 77.8%  | 188.0%  | -0.4   | 4.8    |
| 2023-2025  | 253.0%  | 74.8%  | 218.0%  | 1.6    | 5.6    |

**Analysis:**

*   **CAGR:** The Compounded Annual Growth Rate shows significant volatility, ranging from negative returns to very high positive returns. This indicates a high-growth, high-risk stock.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant potential for losses.
*   **Alpha:** The Alpha values are also highly variable, showing periods of substantial outperformance and underperformance relative to the benchmark.
*   **Beta:** The Beta values are generally low, suggesting that TGTX's price is not highly correlated with the overall market (S&P 500). However, the recent Beta of 1.6 suggests increased market sensitivity.
*   **Cap(B):** The Market Capitalization fluctuated showing growth over time.

### 2. Recent Stock Price Movements

*   **Current Price:** $35.5
*   **Previous Close:** $34.64
*   **Change:** 2.48%
*   **5-Day Moving Average:** 35.23
*   **20-Day Moving Average:** 32.71
*   **60-Day Moving Average:** 32.75

**Analysis:**

*   The stock price is above its 5, 20, and 60-day moving averages, suggesting a short-term upward trend.
*   The recent price increase of 2.48% indicates positive momentum. The price has significantly moved above 20,60-day averages, which suggests strong upward momentum.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment)
*   **RSI:** 69.21 (Approaching overbought territory)
*   **PPO:** 1.23
*   **Hybrid Signal:** Buy 100%
*   **Recent Relative Divergence Change (20-day):** 6.2% (Positive - Short-term increase in divergence)
*   **Expected Return:** -45.4% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI suggests a "Medium Investment" recommendation.
*   The RSI is approaching the overbought level (typically above 70), which could signal a potential pullback.
*   The positive PPO indicates that the short-term moving average is above the long-term moving average, confirming the upward trend.
*   The "Buy 100%" hybrid signal suggests a strong bullish outlook.
*   The 6.2% increase in relative divergence indicates a recent increase in outperformance compared to the S&P 500.
*   **Important Consideration:** The negative expected return (-45.4%) suggests that, from the current point, long-term returns may underperform the S&P 500. This could reflect the recent high performance and potential for mean reversion.

### 4. Recent News & Significant Events

*   **[2025-09-24] Positive Briumvi Data:** TG Therapeutics announced positive 6-year data for Briumvi, showing a high percentage of multiple sclerosis patients free from progression.
*   **[2025-09-17] Analyst Price Target Increase:** B. Riley raised its price target on TG Therapeutics to $55, maintaining a "Buy" rating.
*   **[2025-09-12] Insider Selling:** A TG Therapeutics insider sold shares worth $672,268.

**Analysis:**

*   The positive Briumvi data is a significant catalyst for the stock and supports the bullish sentiment.
*   The analyst price target increase further validates the positive outlook.
*   Insider selling can sometimes be a cause for concern, but it needs to be evaluated in the context of overall insider activity and company performance.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.75)
*   **Target Price:** Average: $40.83 / High: $55.00 / Low: $11.00

**Analysis:**

*   The analyst consensus is "Buy," indicating a positive outlook for the stock.
*   The average target price of $40.83 suggests potential upside from the current price of $35.5.
*   The wide range between the high and low target prices reflects the uncertainty and variability associated with biotech stocks.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2025-08-08 | 0.19 | 0.14 B$      |
| 2025-05-09 | 0.03 | 0.12 B$      |
| 2024-11-07 | 0.03 | 0.08 B$      |
| 2024-08-09 | 0.05 | 0.07 B$      |
| 2025-08-08 | 0.05 | 0.07 B$      |

**Analysis:**

*   The company's recent EPS and revenue figures show improving performance.
*   The most recent quarter (2025-08-08) shows a significant increase in EPS, suggesting positive momentum.
*   Revenue has also been generally trending upwards.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-06-30   | $0.14B   | 86.58%        |
| 2025-03-31   | $0.12B   | 87.14%        |
| 2024-12-31   | $0.11B   | 85.77%        |
| 2024-09-30   | $0.08B   | 88.86%        |
| 2024-06-30   | $0.07B   | 88.70%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE     |
|--------------|----------|---------|
| 2025-06-30   | $0.28B   | 10.20%  |
| 2025-03-31   | $0.24B   | 2.13%   |
| 2024-12-31   | $0.22B   | 10.49%  |
| 2024-09-30   | $0.19B   | 2.02%   |
| 2024-06-30   | $0.18B   | 3.87%   |

**Analysis:**

*   **Revenue and Profitability:** The company has shown consistent growth in revenue over the past few quarters. The profit margins are exceptionally high, indicating strong pricing power or cost management.
*   **Capital and Profitability:** Equity has increased over time, reflecting the company's growth. ROE (Return on Equity) has fluctuated but shows strong performance in some quarters.

### 7. Overall Summary

TG Therapeutics (TGTX) presents a mixed but generally positive picture.

**Key Positives:**

*   **Strong Outperformance:** TGTX has significantly outperformed the S&P 500.
*   **Positive Clinical Data:** Recent positive data for Briumvi is a strong catalyst.
*   **Analyst Support:** Analyst consensus is "Buy," and price targets suggest potential upside.
*   **Improving Financials:** Revenue and EPS are showing positive trends. High profit margins and growing equity are encouraging.
*   **Positive Momentum:** Recent price action and technical indicators (PPO, Hybrid Signal) suggest positive momentum.

**Key Risks/Concerns:**

*   **High Volatility:** Historical data shows significant volatility (high MDD, variable Alpha).
*   **RSI Overbought:** RSI approaching overbought territory may indicate a potential pullback.
*   **Negative Expected Return:** Long-term expected return is negative relative to the S&P 500, suggesting the stock may be overvalued in the short term.
*   **Insider Selling:** Recent insider selling could be a concern, although the impact needs to be assessed in context.

**Conclusion:**

TGTX appears to be a high-growth, high-risk stock with significant potential upside, driven by positive clinical data and improving financials. However, investors should be aware of the inherent volatility and potential for underperformance in the long term. The high profit margins may not be sustainable long term. A careful risk assessment is warranted before investing.
